Use of ureidomustine (BO-1055) in cancer treatment

• 收藏
• 分享

专利权人:

Memorial Sloan Kettering Cancer Center;Academia Sinica

发明人:

Moore, Malcolm,Shieh, Jae-Hung,Su, Tsann-Long,Lee, Te-Chang

申请号：

AU2016308116

公开号：

AU2016308116A1

申请日:

2016.08.17

申请国别(地区):

AU

年份:

2018

代理人:

摘要：

Method of using ureidomustine (BO-1055), a water-soluble NDA cross-linking agent, in the treatment of a cancer, selected from the group consisting of various types of human leukemia [such as acute myeloid leukemia (ALL) and acute B Lymphoblastic leukemia (B-ALL)], lymphomas, small lung cell carcinoma (SCLC), sarcomas, and others.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/